Business Wire

Children and young people encounter multiple forms of gender-based violence – an online course produced by an international project coordinated by Tampere University helps to identify and prevent it

24.1.2022 13:05:00 EET | Business Wire | Press release

Share

Children and young people are exposed to a wide range of gendered violence. However, the phenomenon is poorly understood, which makes helping the victims difficult. The international Education and Raising Awareness in Schools to Prevent and Encounter Gender-Based Violence (EraseGBV) project, coordinated by Tampere University, produced an online course to help identify, prevent and address gender-based violence.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220124005334/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

“Gender-based violence against children and youths is a little-known phenomenon. A better understanding of the issue by professionals working with children and young people is key to identifying violence and its consequences,” says Associate Professor Marita Husso from Tampere University. (Photo: Business Wire)

How do you approach young people who experience discrimination based on their gender expression? How do you deal with offensive images of your student, for example, on social media? And how do you address sexual violence faced by children or young people? Violence against children and youths is often referred to as bullying, even when it is considered assault by the Criminal Code.

“Gender-based violence against children and youths is a little-known phenomenon. A better understanding of the issue by professionals working with children and young people is key to identifying violence and its consequences,” says Associate Professor Marita Husso from Tampere University.

Husso leads the international Education and Raising Awareness in Schools to Prevent and Encounter Gender-Based Violence (EraseGBV) project coordinated by Tampere University, which has just published a free online course on encountering gender-based violence at schools in English, Finnish and Swedish. The training is also produced in Croatian, Spanish and Catalan.

It is a research-based e-learning package that develops new skills for those working in education, social work and health services. The training is aimed specifically at professionals working with 13–19-year-old teenagers but is also suitable for use with younger and older students. The training looks at the phenomenon from the perspectives of the person experiencing violence, the perpetrator, bystanders, and professionals and experts.

Schools play a pivotal role

Schools play a key role in identifying and addressing violence. The social environment of schools provides an opportunity to learn interaction skills and offers a unique opportunity to influence the perceptions and behaviour of children and young people. At the same time, it enables awareness-raising and change towards more equal relationships and more ethical practices.

“Addressing violence is a prerequisite for promoting equality and sustainable development. This new online training provides tools for preventing, identifying, and addressing violence. It provides information on such issues as digital violence, the impact of violence, good practices and legislation on the subject," says Husso.

“Getting help for problems of violence depends on the problem first being identified and addressed,” she emphasises.

The EraseGBV project has researched gender-based violence and ethical agency in schools and education in Finland, Croatia and Spain. The research partners comprise Tampere University; the University of Zagreb; Blanquerna Ramón Llull University; the Centre for Education, Counselling and Research (CESI); and Conexus.

For more information and instructions on how to register, please see the link to further information and the online course: https://projects.tuni.fi/erasegbv/training-programme/

Photo: In her future projects, Associate Professor Marita Husso will focus on promoting nonviolence and sustainable wellbeing and exploring harmful ideological, institutional and affective practices related to violence. Photo by Hanna-Kaisa Hämäläinen

Tampere University

The multidisciplinary Tampere University is the second largest university in Finland. The spearheads of our research and learning are technology, health, and society. The University is committed to addressing the greatest challenges that are facing our society and creating new opportunities. Almost all the internationally recognised fields of study are represented at the University. Together, Tampere University and Tampere University of Applied Sciences comprise the Tampere Universities community made up of more than 30,000 students and close to 5,000 employees. www.tuni.fi/en

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Enquiries:
Associate Professor Marita Husso
Faculty of Social Sciences, Tampere University
marita.husso@tuni.fi, tel. +358503182510

University Researcher Satu Lidman
Faculty of Social Sciences, Tampere University
satu.lidman@tuni.fi

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye